In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Galmed Pharmaceuticals (GLMD), with a price target of $20. The company’s shares opened today at $9.54.
McCarthy said:
“Galmed announced that the P2b data from the ARREST trial in NASH, presented during the late-breaking abstract oral presentation at The Liver Meeting, was selected for inclusion in The Best of The Liver Meeting 2018.”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.7% and a 31.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Galmed Pharmaceuticals with a $37.50 average price target, representing a 293.1% upside. In a report issued on November 5, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $59 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.06 and a one-year low of $3.61. Currently, Galmed Pharmaceuticals has an average volume of 154.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders.
